3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Terminated
2
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Thoracic
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Pancreatic Neoplasms
2
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Melanoma
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Cyclophosphamide
1488
Cisplatin
1410
Paclitaxel
1316
Radiotherapy
1259
Carboplatin
1247
Gemcitabine
1214
Docetaxel
1110
Bevacizumab
1029
Fluorouracil
894
Doxorubicin
786
Dexamethasone
746
Rituximab
719
Capecitabine
716
Oxaliplatin
700
pembrolizumab
673
Etoposide
673
Irinotecan
634
Filgrastim
621
Cytarabine
584
Leucovorin
578
Nivolumab
557
Vincristine
510
Prednisone
474
Cetuximab
464
Bortezomib
457
Erlotinib Hydrochloride
456
Trastuzumab
448
Methotrexate
437
Lenalidomide
426
Pemetrexed
419
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Interventional
×
pegilodecakin
×
Clear all
NCT02009449
2024-11-15
IVY
Eli Lilly and Company
Phase 1
Completed
353 enrolled
NCT02923921
2020-10-19
Sequoia
Eli Lilly and Company
Phase 3
Completed
567 enrolled
17 charts